In This Section

ncRNAs in Drug Metabolism and the Translation of Gene Silencing Technology into Therapeutics

Sunday April 07, 2019

8:00 am - 10:00 am Eastern Time (ET)

Room W206 C

CVP DDD DMDD TOX

Chair :

Baitang Ning
Natl Ctr for Toxicological Research, FDA

Julie Lade
Amgen, Inc. USA



Piled evidence has demonstrated that non-coding RNAs (ncRNAs) play an important role in mediating the inter-individual variability observed in drug metabolism through the modulation of genes encoding drug metabolizing enzymes and transporters (DMETs) in addition to nuclear receptors. In contrast to the mechanism by which endogenous ncRNAs impact gene expression, synthetic interfering RNA (siRNA) has become rapidly under investigation as a therapeutic strategy to inhibit the translation of messenger RNA in an effort to treat human diseases. This symposium will provide a blended overview of recent research pertaining to ncRNAs and exogenous oligonucleotides within the context of drug metabolism and gene silencing, respectively.

Speakers

Dianke Yu - School of Public Health, Qingdao University

Functional Characterization of ncRNAs in the Regulation of CYPs

Michael Court - Washington State University, USA

Regulation of UGTs by MicroRNAs and Drug Toxicity

Faraz Kazmi - Janssen Research & Development

Inhibition of Drug Metabolizing Enzymes and Drug Transporters by Phosphodiester- or Phosphorothioate-linked Oligonucleotides

Sara Humphreys - PKDM, Amgen Inc.

siRNA-protein Interactions in the Context of siRNA-based Therapeutics

Hannah Petrek - UC Davis

Bioengineering of Single ncRNA Molecule for Multi-Targeting Against NSCLC

Last Updated: August 15, 2019
Key Dates
April 6

ASPET Business Meeting and Awards Presentation

April 6-9

ASPET Annual Meeting at EB 2019